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women with borderline or mildly dyskaryotic cervical smear test
results: 6-month follow-up
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Research Centre, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK
State anxiety (S-STAI-6), distress (GHQ-12), concern and quality of life (EuroQoL-EQ-5D) 6 months after human papillomavirus
(HPV) testing in women with borderline or mildly dyskaryotic smear test results were assessed based on a prospective
questionnaire study, with 6-month follow-up after the smear test result. Two centres participated in an English pilot study of HPV
testing. Participants included two groups of women receiving abnormal smear test results: (tested for HPV and found to be (a) HPV
positive (n¼ 369) or (b) HPV negative (n¼ 252)) and two groups not tested for HPV (those receiving (c) abnormal smear test
results (n¼ 102) or (d) normal smear test results (n¼ 288)). There were no differences in anxiety, distress or health-related quality of
life between the four study groups at 6 months. Levels of concern about the smear test result remained elevated in all groups
receiving an abnormal smear test result, and were highest in the group untested for HPV. Predictors of concern across all groups
receiving an abnormal smear test were perceived risk of developing cancer, being HPV positive or untested for HPV, sexual health
worries and the smear being a woman’s first smear test. The raised anxiety and distress observed in women immediately after being
informed of an abnormal smear test result and that they are HPV positive was no longer evident at 6 months. Concern about the
smear test result was however still raised in these women and those who tested negative for HPV, and particularly among those who
did not undergo HPV testing.
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There is growing interest in human papillomavirus (HPV) testing
as part of the management of women with cytological abnormal-
ities (Petry et al, 2003). This is reflected in the English pilot study
evaluating the use of HPV testing in women with borderline or
mildly dyskaryotic smear test results. However, concern has been
expressed about its potential to raise anxiety beyond that
commonly reported after the receipt of a borderline or mildly
dyskaryotic result (McCaffery et al, 2002). Receipt of abnormal
smear test results and referral for colposcopy are associated with
high anxiety levels (Marteau et al, 1990; Lerman et al, 1991;
Rogstad, 2002), some of which can be avoided by the provision of
clear, salient information (Wilkinson et al, 1990; Marteau et al,
1996). We have documented that informing women that they have
a borderline or mildly dyskaryotic cervical smear test result and
that they are infected with HPV is associated, in the first 4 weeks of
receiving such test results, with raised state anxiety, general
distress and concern about the test result, above the level found in
women who test negative for HPV and those not undergoing HPV
testing (Maissi et al, 2004). We have also documented that receipt
of an HPV-negative test result does not appear to reassure women
receiving a borderline or mildly abnormal smear test result.
We report here the 6-month follow-up data for these women.
We predicted that, in keeping with systematic review evidence,
raised levels of anxiety, distress and concern will no longer be
evident 6 months after the receipt of such test results (Shaw et al,
1999).
In addition, we report data on health-related quality of life
(HRQoL). To date, most economic evaluations only report on the
effectiveness of screening in terms of lives or life year gained.
HRQoL data permit analysts to incorporate quality of life
information directly into economic evaluations.
MATERIALS AND METHODS
Participants
All women who underwent a routine cervical smear test at one of
two centres taking part in the English pilot study of Liquid Based
Cytology (LBC) and HPV testing (2002–2003), and who received
either a normal or a borderline/mildly dyskaryotic test result, were
eligible for this study. They were informed of the possibility of
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being invited into this questionnaire-based study in the letter
inviting them to attend for screening. All borderline or mildly
dyskaryotic smear samples were tested for HPV. Following the end
of HPV testing in the pilot, an extra group of women with such
smear test results but no HPV testing was recruited to allow for the
assessment of the possible reassuring effects of receiving an HPV-
negative test result.
A total of 2183 women was sent a questionnaire within a week
of the research team being informed that their smear test results
had been sent to them. Up to two reminders were sent, within 14
and 28 days. The baseline sample of 1376 (63%) women comprised
366 women who had received a normal test result and 1010 women
who had received a borderline or mildly dyskaryotic smear test
result. Of this latter group, 331 were HPV negative, 536 were HPV
positive and 143 were not tested for HPV.
Of the 1376 women in the initial sample, 1011 (74%) completed
a second questionnaire 6 months after the receipt of their test
results. The response rate varied significantly between the groups
(w2(3)¼ 12.542, P¼ 0.006), with 79% responding in the normal test
result group (n¼ 288), 76% in the HPV-negative group (n¼ 252),
69% in the HPV-positive group (n¼ 369) and 71% for the group
not tested for HPV (n¼ 102).
Responders at 6 months were compared with nonresponders on
demographic characteristics (age, education, ethnic status, smear
test history) as well as baseline measures of anxiety, distress,
quality of life and concern.
Responders were significantly older (mean(s.d.)¼ 37.5(11.6))
than nonresponders (33.5(11.1); Po0.001) and more likely to
have had a previous smear test (91.5 vs 81.4%; Po0.001), but there
were no significant differences in ethnic status or education.
Comparing psychological outcomes immediately after receipt
of the smear test result, responders differed from nonresponders
in anxiety (mean(s.d.)¼ 33.7(11.3) vs 35.9(12.0); P¼ 0.003),
distress (mean(s.d.)¼ 2.3(3.1) vs 2.7(3.2); P¼ 0.039) and concern
(mean(s.d.)¼ 4.2(2.0) vs 4.6(1.9); P¼ 0.002), but not in HRQoL.
Main outcome measures
State anxiety was assessed using the short form of the state scale of
the Spielberger State-Trait Anxiety Inventory (S-STAI-6) (Marteau
and Bekker, 1992), prorated to give a scale range from 20 to 80.
The scores for women who had completed at least three of the six
items (50%) were prorated to maximise the use of available data.
The population norm for women is 35 (Spielberger et al, 1970).
The internal reliability (Cronbach’s a) of the scale in this study
sample was 0.85 (n¼ 963).
General distress was assessed using the 12-item General Health
Questionnaire (GHQ-12) (range 1– 12 with a cutoff point of 4
indicating clinical caseness (a¼ 0.90, n¼ 989)) (Bridges and
Goldberg, 1986).
Health-related quality of life was assessed using the EuroQol
EQ-5D questionnaire. Valuations of responders’ health states were
assigned using the results from a UK general population survey to
estimate utility values on a scale of 0 to 1, where 1 is perfect
subjective health and 0 is death (Dolan et al, 1995).
Concern about the smear result 6 months earlier was assessed
using a 7-point rating scale asking women how concerned they felt
about the smear test result, with higher scores indicating greater
concern.
Perceived risk of developing cervical cancer was assessed using a
7-point rating scale assessing women’s perceptions of their
likelihood of developing cervical cancer in the next 10 years:
higher scores indicate greater perceived risk.
Sexual health worries were assessed in the three study groups
with borderline or mildly dyskaryotic test results using six items
(range 1–5), five of which were taken from the standardised
Psychosocial Effects of Abnormal Pap Smears Questionnaire
(PEAPS-Q) (Bennetts et al, 1995). An extra item (‘Have you been
worried about whether your test result would have a bad effect on
your relationship with your partner?’) was added to address an
issue raised by women during the initial phase of the study. Higher
scores on the scale indicate greater worry (a¼ 0.85, n¼ 664).
Repeat smear, HPV and colposcopic examinations: The results of
further cervical smear tests and colposcopic examinations were
assessed from laboratory records after 6 months. These were used
to categorise women as having either normal or abnormal smear
test results at 6 months. Normal results include normal repeat
smear test results, a negative HPV test result and normal
colposcopy results. Abnormal results include all categories of
abnormal repeat smear test results (regardless of HPV status),
women who were HPV positive but had normal cytology and
women with all categories of abnormal colposcopy results.
Demographic information: Age, highest educational qualifica-
tion, ethnic background and smear history were reported at the
initial assessment.
Statistical analysis
Differences in the demographic and smear history characteristics
of the four groups were assessed using ANOVA (for age,
perceptions of the risk of developing cervical cancer and sexual
health worries) and w2 tests. For comparisons at baseline, ANOVA
with linear trend was used with a priori linear contrasts after
adjusting means for baseline differences in age and smear history.
Since the four groups were not expected to differ at 6-month
follow-up, comparisons were made using ANOVA with Tukey B
post hoc tests to test for between-group differences where
indicated. Hierarchical multiple linear regression was used to
ascertain the best predictors of concern at the follow-up
assessment point in the three groups of women with borderline
or mildly dyskaryotic smear test results.
RESULTS
The groups differed in age, whether the studied smear test 6
months previously was their first one or not, and whether the test
was a repeat of a smear following an abnormal smear test result
(Table 1). Women with borderline or mildly dyskaryotic smear test
results who were HPV positive were the youngest and, related to
this, it was more likely that the studied smear test was their first
ever smear test, in comparison with women in the other groups.
Analysis of variance of means adjusted for age and smear
history revealed that at follow-up the groups significantly differed
in concern (F3, 996¼ 83.39, Po0.001), but not in anxiety
(F3, 961¼ 0.40, P¼ 0.752), distress (F3, 980¼ 0.81, P¼ 0.487) or
HRQoL (F3, 989¼ 0.70, P¼ 0.554) (Table 2). Post hoc tests showed
that concern was significantly lower in the ‘normal’ group and
highest in the ‘HPV untested’ group, while women who were either
HPV positive or HPV negative did not differ significantly in their
levels of concern (Tukey B post hoc test, Po0.05).
The four groups also differed in their perceived risks of
developing cervical cancer (F3,985¼ 14.88, Po0.001). Women
who were either HPV positive or untested for HPV perceived
their risks of developing cervical cancer as significantly higher
than women with normal smear test results and women who tested
negative for HPV.
Overall, none of the three groups with abnormal test results was
extremely worried about their sexual health. The group with HPV-
positive test results did however score significantly higher than the
other two groups (F2,666¼ 30.64, Po0.001; Tukey B post hoc test,
Po0.05).
Table 3 shows the variables entered into the hierarchical
multiple linear regression to identify the predictors of concern 6
months after the initial assessment, in the three groups with
borderline/mildly dyskaryotic smear test results.
Psychological impact of HPV testing: 6-month follow-up
E Maissi et al
991
British Journal of Cancer (2005) 92(6), 990 – 994& 2005 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
Four variables independently predicted concern (R2¼ 0.29,
Po0.001): HPV status (not HPV tested b¼ 0.17, Po0.001; HPV
positive b¼ 0.14, P¼ 0.001), the studied smear having been a
woman’s first smear test (b¼ 0.08, P¼ 0.035), perceived risk of
developing cervical cancer (b¼ 0.43, Po0.001) and sexual health-
related worries (b¼ 0.15, Po0.001).
Women’s comments on their questionnaires illustrating some of
these predictors are provided in Box 1.
DISCUSSION
As predicted, the receipt of a borderline or mildly dyskaryotic
cervical smear test result 6 months earlier, with or without HPV
testing, was no longer associated with the raised levels of state
anxiety, or general distress seen within the first month of receipt of
such test results. Similarly, there were no significant differences in
HRQoL between the four study groups at 1 or 6 months. The raised
levels of concern detected may not have had a significant impact
on patient’s HRQoL. Alternatively, women’s HRQoL may have
been affected but the EQ-5D may not have been sufficiently
sensitive to detect it, as has been found in other contexts
(Jenkinson et al, 1997).
Contrary to our predictions, concern about the test result was
still raised 6 months later in women who had received an abnormal
smear test result regardless of whether they had undergone HPV
testing and regardless of whether they were HPV positive or
Table 1 Demographic and clinical characteristics of the four study groups
Normal
Abnormal HPV
negative
Abnormal HPV
not tested
Abnormal HPV
positive
n¼ 288 n¼ 252 n¼102 n¼ 369 Anova and v2 tests P
Age in years mean (s.d.) 40.5 (12.1) 41.6 (11.1) 36.6 (11.1) 32.7 (9.8) F¼ 43.20 o0.001
College education: (% (n)) 46.7 (128) 37.5 (90) 46.8 (44) 48.5 (172) w2¼ 7.61 0.055
White ethnic background (% (n)) 97.9 (282) 96.8 (242) 97.9 (94) 97.0 (353) w2¼ 0.94 0.817
First smear test at baseline (% (n)) 7.0 (20) 3.2 (8) 5.9 (6) 13.9 (51) w2¼ 24.70 o0.001
Repeat smear result (% (n))
Not available NA 25.8 (65) 39.2 (40) 49.9 (184)
Abnormala NA 7.9 (20) 23.5 (24) 46.1 (170) w2¼ 288.99 o0.001
Normal NA 66.3 (167) 37.3 (38) 4.1 (15)
aAbnormal repeat smear test result includes all categories of abnormal cytology (regardless of HPV status), HPV-positive status but normal cytology and all abnormal colposcopy
results.NA¼ not applicable.
Table 2 Psychological outcomes (adjusted means, s.e.) at baseline and 6-month follow-up assessments
Normal Abnormal HPV negative Abnormal HPV not tested Abnormal HPV positive
n¼ 288 n¼ 252 n¼102 n¼369 F (P)
State anxiety (S-STAI-6)
Baseline 36.1 (0.7)a 37.5 (0.8)b 37.1 (1.3)b 38.6 (0.7)c 5.73 (0.017)
Follow-up 36.8 (0.8) 35.7 (0.8) 36.7 (1.3) 36.7 (0.7) 0.40 (0.752)
Emotional distress (GHQ-12)
Baseline 2.0 (0.2)a 2.2 (0.2)b 2.1 (0.3)b 2.7 (0.2)c 8.78 (0.003)
Follow-up 2.0 (0.2) 2.0 (0.2) 1.9 (0.3) 2.3 (0.2) 0.81 (0.487)
Concern about test result
Baseline 2.3 (0.1)a 4.6 (0.1)b 4.7 (0.2)b 5.2 (0.1)c 488.31 (o0.001)
Follow-up 2.0 (0.1)a 3.5 (0.1)b 4.4 (0.2)c 3.8 (0.1)b 83.39 (o0.001)
HRQoL (EQ-5D)
Baseline 0.91 (0.02) 0.89 (0.02) 0.87 (0.02) 0.88 (0.02) 0.91 (0.340)
Follow-up 0.86 (0.02) 0.90 (0.02) 0.88 (0.04) 0.89 (0.02) 0.70 (0.554)
Perceived risk
Baseline 3.3 (0.1)a 3.8 (0.2)b 4.3 (0.2)b 4.7 (0.1)c 55.06 (o0.001)
Follow-up 3.0 (0.2)a 3.3 (0.2)a 4.7 (0.3)b 4.1 (0.1)b 14.88 (o0.001)
Sexual health worries
Baseline NA NA NA NA
Follow-up NA 1.0 (0.1)a 1.1 (0.1)a 1.8 (0.1) 30.64 (o0.001)
Values sharing the same superscripts are not significantly different (Planned linear contrasts (baseline); Tukey post hoc tests (follow-up)). NA¼ not available.
Table 3 Hierarchical multiple linear regression analysis predicting
concern at the 6-month follow-up assessment for the three groups with
borderline or mildly dyskaryotic smear test results
Block
R2
(Po0.001) Variable b (P)
Smear test result
and history
0.039 HPV positivea 0.11 (0.009)
HPV not testeda 0.16 (o0.001)
Previous smear: noneb 0.11 (0.006)
Previous smear: abnormalb 0.01 (0.723)
Demographics 0.061 Age 0.11 (0.007)
Education 0.12 (0.003)
Repeat smear 0.072 Repeat smear: normalc 0.07 (0.109)
Repeat smear: abnormalc 0.02 (0.717)
Psychological 0.286 Perceived risk 0.41 (o0.001)
Sexual health worries 0.10 (0.005)
aReference group was HPV negative. bReference group was previous test normal/not
known to be abnormal. cReference group was ‘not available’.
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negative. Concern was greatest in women who had not undergone
HPV testing.
The four predictors of concern at the 6-month follow-up were
HPV status, smear history, sexual health worries at follow-up and
high perceived risk of developing cervical cancer. Of these, the
largest predictor was perceived risk of developing cervical cancer.
We did not ask women to quantify the likelihood that they could
develop cervical cancer. It is therefore a hypothesis that their concern
reflects an overestimate of the likelihood of developing cervical
cancer given their test results. This could be tested by providing
women with information on their relatively higher but absolute low
levels of risk and assessing their subsequent levels of concern.
While being classified as having a normal test result at 6 months
was predictive of lower concern, it explained relatively little of the
variance. As can be seen from Table 1, for many women the results
of repeat investigations were unavailable at the time of the 6-
month follow-up. Where results were available, very few of the
women who were HPV positive were subsequently classified as
having normal test results.
Sexual worries were higher in women infected with HPV and
were predictive of concern across the three groups receiving
borderline or mildly dyskaryotic smear test results. We were
unable to include a comparison group of women infected with
HPV and normal smear test results as, according to the protocol of
the LBC/HPV pilot, such smear samples were not further tested for
HPV. Therefore, it was not possible to ascertain the concern and
sexual worries that an HPV-positive result alone can lead to.
As illustrated in Box 1, many women reported trying in vain to
find more information on the implications of HPV infectivity for
partners. While some of this information is clearly lacking at
present, it may be that providing women before testing with more
of the available information about the sexually transmitted nature
of HPV may better prepare them for learning that they are infected.
Women undergoing their first as opposed to a subsequent smear
test are more likely to be experiencing concern 6 months after an
abnormal smear test result. Neither age nor educational level was
predictive. Whether this reflects no experience of a test result,
normal or abnormal, or less knowledge about the screening test is
unknown. It does however suggest the importance of ensuring that
women undergoing their first smear test are helped to understand
both the frequency and meaning of borderline/mildly dyskaryotic
smear test results.
In contrast to responses within a month of receiving test results,
there was some evidence 6 months later that women receiving a
borderline or mildly abnormal smear test result were somewhat
reassured by learning that they were HPV negative. While concern
about their test results was similar to that of women who were
HPV positive, nonetheless women who were HPV-negative
perceived their risks of developing cervical cancer as lower and
similar to those of women receiving normal test results. Although
an HPV-negative result can be reassuring in terms of lowering the
risk of cervical cancer, thinking of one’s risk as similar to that
following a normal smear test result could reflect false reassurance,
which could adversely affect regular attendance for smear tests.
Borderline or mildly dyskaryotic cervical smear tests are
relatively common, occurring in about 7% of cervical smear tests
taken (1998/1999 figures for England). Similarly, rates of HPV
infection are high, occurring in about 20% of women aged between
18 and 35 and about 7% of those aged over 50 (Cuzick et al, 1999).
Rates of infection in those with borderline or mildly dyskaryotic
smear test results are more than double these rates (unpublished
report submitted to Department of Health, May 2004). Perceptions
of the prevalence of a health threat affect how serious it is
perceived to be, with threats perceived as more common being
seen as less serious (Croyle and Jemmott, 1991). It is therefore
possible that informing women of the frequency with which their
test results are obtained would reduce concern. It would however
be important before doing so to establish that such concern was
not important in motivating women to attend for the recom-
mended repeat smear tests or treatment. It is unknown to what
extent the raised levels of concern found at 6 months are
appropriate, acting to motivate women to follow recommended
actions to reduce the risk of cervical cancer. We have recently
found that general anxiety but not concern predicts attendance for
a repeat smear test following an inadequate smear test result
(unpublished data, submitted for publication). We therefore
predict that raised concern is not adaptive, reflecting an over-
estimation of the likelihood of developing cervical cancer, which is
more likely to demotivate than to motivate re-attendance. Thus, if
HPV testing is incorporated in the primary care cervical screening
services either for all women or only those with borderline/mild
dyskaryotic cytology, clear information needs to be provided about
HPV, including the absolute and relative risks of cervical cancer
that HPV infection bestows.
Limitations of the study
A total of 27% of the women who agreed to take part in the initial
assessment did not complete the follow-up questionnaire reported
in this paper. Those who were HPV positive who responded at the
Box 1 Written comments from women
Borderline/mildly dyskaryotic and HPV-positive smear test result
1. My initial smear showed evidence of the HPV virus and abnormalities. I was very worried. My GP didn’t have any information on this and the NHS Direct provided
information that scared me (participant 490).
2. I still haven’t been given any advice from my GP, practice nurse or colposcopy clinic or NHS Direct despite asking. I have since found HPV is a contributory factor in
those who have cervical cancer so why is there no information available for me or my partner? (participant 304).
Borderline/mildly dyskaryotic and HPV-negative smear test result
1. I am still very angry that after my ‘minor changes’ result no-one could give me any statistics or guidance on how likely it would be to worsen/get better/stay the same.
NHS Direct were hopeless and gave me incorrect information. I finally spoke to a doctor at the GU clinic who told me since I tested negative for HPV she was 99% sure
there was no problem. It took one and a half months of worry and speaking to different people before I heard this. Surely if you test for HPV, if the result is negative one
should be told what a good thing this is? (participant 469)
2. I do not consider enough information was given after repeat smear when test still showed abnormal cells. I had to visit GP for explanation of why I don’t need
another smear test for 5 years despite abnormal cells existing (participant 058).
Borderline/mildly dyskaryotic smear test result, not tested for HPV
1. I have been told for the past two years or so that my smear test has been borderline, but nothing serious, just to keep an eye on things. I feel now that this has gone
on for so long that I need to speak to my GP again (participant 923).
2. Although the nurses have been good at reassuring me and answering any questions I think the repeat smear results take too long to come through and it still a
nervous time (participant 919).
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6-month follow-up were less anxious immediately after receipt of
their test results than those who did not respond. It is therefore
possible that the pattern of results we report here at 6 months
under-represents the anxiety, distress and concern present for
these women at 6 months.
Women from ethnic minorities and those with lower levels of
education were also under-represented in our sample. While we
did not find that education level predicted concern, the study had
insufficient power to assess the possible moderating effects of
ethnicity on psychological responses to HPV testing.
Concluding comment
The raised anxiety and distress observed in women immediately
after being informed that they had an abnormal smear test result
and were HPV positive is no longer evident 6 months later.
Concern about the smear test result is, however, still raised in these
women as well as those who received an HPV-negative test result
and particularly in those who did not undergo HPV testing.
Concern may be reduced by informing women of the relatively low
absolute chance that they will develop cervical cancer, and that the
prevalence of their particular test result is relatively high.
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